Log in

NASDAQ:TSRO - TESARO Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$74.96
0.00 (0.00 %)
(As of 01/18/2019)
Today's Range
$74.94
Now: $74.96
$74.97
50-Day Range N/A
52-Week Range
$23.41
Now: $74.96
$75.16
Volume1.19 million shs
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$223.33 million
Book Value$4.58 per share

Profitability

Net Income$-496,120,000.00
Net Margins-295.67%

Miscellaneous

EmployeesN/A
Market Cap$4.13 billion
Next Earnings DateN/A
OptionableOptionable

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.


TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) announced its quarterly earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to analysts' expectations of $65.50 million. TESARO had a negative net margin of 295.67% and a negative return on equity of 1,209.72%. TESARO's revenue for the quarter was up 94.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.82) EPS. View TESARO's Earnings History.

Has TESARO been receiving favorable news coverage?

Media headlines about TSRO stock have been trending somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. TESARO earned a daily sentiment score of 2.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for TESARO.

Who are some of TESARO's key competitors?

What other stocks do shareholders of TESARO own?

Who are TESARO's key executives?

TESARO's management team includes the folowing people:
  • Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)
  • Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)
  • Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)
  • Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)
  • Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43)

What is TESARO's stock price today?

One share of TSRO stock can currently be purchased for approximately $74.96.

How big of a company is TESARO?

TESARO has a market capitalization of $4.13 billion and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. View Additional Information About TESARO.

What is TESARO's official website?

The official website for TESARO is http://www.tesarobio.com/.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for TESARO (NASDAQ TSRO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  643 (Vote Outperform)
Underperform Votes:  505 (Vote Underperform)
Total Votes:  1,148
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel